Medically reviewed on March 27, 2017.
Applies to the following strengths: 50 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Prostate Cancer
50 mg orally once a day, given at the same time each day.
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
Mild hepatic impairment: No adjustment recommended
Moderate to severe hepatic impairment: Caution is advised due to possible increased accumulation of bicalutamide.
Bicalutamide should be used with caution in patients with moderate to severe hepatic impairment. Bicalutamide is extensively metabolized by the liver. Limited data in subjects with severe hepatic impairment suggest that excretion of bicalutamide may be delayed and could lead to further accumulation. Periodic liver function tests should be considered for patients on long-term therapy.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Bicalutamide is not dialyzable.
For treating prostate cancer, luteinizing hormone-releasing hormone (LHRH) analog therapy should be started at the same time as treatment with bicalutamide. Regular assessments of serum prostate specific antigen (PSA) may be helpful in monitoring patient response. For patients who have evidence of progression of disease together with an elevated PSA, a treatment-free period of antiandrogen, while continuing the LHRH analog, may be considered. The dose of bicalutamide when used for any other malignant disease may depend upon the specific indication for its use and whether other cytotoxic agents are coadministered.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about bicalutamide
- Bicalutamide Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 9 Reviews
- Drug class: antiandrogens
Other brands: Casodex